On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderly.

ABSTRACT:

Rationale

Suvorexant is a first-in-class orexin receptor antagonist for treating insomnia. There is a general concern that hypnotics may impair next-morning driving ability.

Objective

The objective of this study was to evaluate next-morning driving performance in older adults after single and repeated doses of suvorexant.

Methods

Double-blind, randomized, placebo-controlled, 4-period crossover study in 24 healthy volunteers (10 females), aged 65-80 years. Subjects were treated with suvorexant (15 and 30 mg) for eight consecutive nights, zopiclone 7.5 mg nightly on days 1 and 8, and placebo. Driving performance was assessed on days 2 and 9 (9 h after dosing) using a 1-h standardized highway driving test in normal traffic, measuring standard deviation of lateral positio

SUBMITTER: Vermeeren A 

PROVIDER: S-EPMC4989000 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature